Lakefront Biotherapeutics (LKFT) Current Taxes (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Current Taxes of $1.1 million for Q1 2026, up 420.54% year-over-year from $205117.5 in Q1 2025, and down 4.05% quarter-over-quarter from $1.1 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Current Taxes (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Current Taxes for 13 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Taxes rose 420.54% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 420.54% YoY), while the FY2025 annual figure was $1.1 million, up 318.23% from the prior year.
- Current Taxes retreated to $1.1 million in Q1 2026 per LKFT's latest filing, from $1.1 million in the prior quarter.
- Across five years, Current Taxes topped out at $3.0 million in Q1 2022 and bottomed at $60252.6 in Q4 2023.
- Historically, Current Taxes has averaged $841687.0 across 5 years, with a median of $408000.2 in 2025.
- Annual changes were most pronounced in 2024 — Current Taxes tumbled 94.67% — and 2026, when it soared 420.54%.
- Lakefront Biotherapeutics' Current Taxes stood at $1.0 million in 2022, then slumped by 94.22% to $60252.6 in 2023, then surged by 341.61% to $266080.3 in 2024, then jumped by 318.23% to $1.1 million in 2025, then slipped by 4.05% to $1.1 million in 2026.
- Business Quant data shows LKFT's Current Taxes at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $408000.2 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 49.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 76.32 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 59,089.99 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 408,000.23 |
| Jun 30, 2025 | 314,684.79 |
| Mar 31, 2025 | 205,117.47 |
| Dec 31, 2024 | 266,080.25 |
| Sep 30, 2024 | 237,215.41 |
| Mar 31, 2024 | 67,354.43 |
| Dec 31, 2023 | 60,252.63 |
| Sep 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 1.26 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Mar 31, 2022 | 2.98 Mn |
| Dec 31, 2021 | 2.04 Mn |
| Jun 30, 2021 | 454,010.33 |
| Dec 31, 2020 | 1.49 Mn |
| Jun 30, 2020 | 1.39 Mn |
| Mar 31, 2020 | 1.26 Mn |
| Dec 31, 2019 | 2.25 Mn |
| Sep 30, 2019 | 1.15 Mn |